Head Office
Novartis International AG
CH-4002 Basel
Switzerland
+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)
Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland
+41 61 324 79 44
investor.relations@novartis.com
Global Media Relations
Eric Althoff
Basel, Switzerland
+41 61 324 7999
eric.althoff@novartis.com
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
If your question is not investment related, please contact the main switchboard:
Novartis International AG
Tel: +41 61 324 11 11
General IR questions, please contact our team.
| Email address: | Investor.relations@novartis.com |
|---|---|
|
Stephen Rubino, PhD Vice President, Investor Relations |
+1 862 778 83 01 |
| Jill Pozarek | +1 212 830 24 45 |
| Edwin Valeriano | +1 212 830 24 56 |
| Mailing address: |
Novartis U.S.A
|
© 2013 Novartis AG Terms of usePrivacy policy Sitemap
